Following discussions with the US regulator, Texan drugmaker Lexicon Pharmaceuticals (Nasdaq: LXRX) now plans to resubmit a New Drug Application (NDA) for sotagliflozin.
The firm announced that, after the receipt of recent feedback from US Food and Drug Administration, the new submission would be completed by mid-2024.
Lexicon is submitting for approval to market sotagliflozin as an adjunct to insulin for glycemic control in people with type 1 diabetes and chronic kidney disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze